Trial
NCT01436305
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Clinical Trials in Organ Transplantation
Condition
Kidney Transplantation
Intervention
Alemtuzumab
Why stopped
Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-27